These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33650745)

  • 1. Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study.
    Yu JK; Iorio A; Chelle P; Edginton AN
    Haemophilia; 2021 May; 27(3):358-365. PubMed ID: 33650745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste.
    D'Albini L; Dorholt M; Gallucci L
    J Manag Care Spec Pharm; 2023 Jan; 29(1):47-57. PubMed ID: 36580124
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.
    Copur MS; Gnewuch C; Schriner M; Tharnish M; Gonen M; McDonald M; Kezeor J; Ramaekers RC; Gauchan D; Clark D; Greenwalt L; Mickey M; Norvell M
    J Oncol Pharm Pract; 2018 Mar; 24(2):116-120. PubMed ID: 29284380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen.
    Bukkems LH; Fischer K; Kremer-Hovinga I; Donners AAM; Fijnvandraat K; Schutgens REG; Cnossen MH; Mathôt RAA
    Thromb Haemost; 2022 Feb; 122(2):208-215. PubMed ID: 33946119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world data approach to determine the optimal dosing strategy for pembrolizumab.
    Jang A; Nakashima L; Ng T; Fung M; Jiwani S; Schaff K; Suess J; Goncalves R; Jang D; Kuik K; Labelle S; Pow A
    J Oncol Pharm Pract; 2021 Apr; 27(3):635-643. PubMed ID: 32539663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding.
    Lindsey S; Parsons LB; Figg LR; Rhodes J
    J Oncol Pharm Pract; 2018 Jan; 24(1):47-55. PubMed ID: 29251257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rounding rituximab dose to nearest vial size.
    Patel S; Le A
    J Oncol Pharm Pract; 2013 Sep; 19(3):218-21. PubMed ID: 23114093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste.
    Donners AAMT; van der Zwet K; Rademaker CMA; Egberts TCG; Schutgens REG; Fischer K
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100074. PubMed ID: 36915864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A.
    Retout S; Schmitt C; Petry C; Mercier F; Frey N
    Clin Pharmacokinet; 2020 Dec; 59(12):1611-1625. PubMed ID: 32504271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential cost savings associated with dose rounding antineoplastic monoclonal agents.
    Francis SM; Heyliger A; Miyares MA; Viera M
    J Oncol Pharm Pract; 2015 Aug; 21(4):280-4. PubMed ID: 24821690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of potential cost savings through chemotherapy and biotherapy dose-rounding at a pediatric institution.
    Graff JM; Cramer J; Kolb LL; Agherrabi Z; Burgess M
    J Oncol Pharm Pract; 2024 Jun; 30(4):705-709. PubMed ID: 37350075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the potential impact of dose rounding parenteral chemotherapy agents on cost savings and drug waste minimization.
    Chillari KA; Southward J; Harrigan N
    J Oncol Pharm Pract; 2018 Oct; 24(7):507-510. PubMed ID: 28732452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of dose rounding of chemotherapy to the nearest vial size.
    Dooley MJ; Singh S; Michael M
    Support Care Cancer; 2004 Sep; 12(9):653-6. PubMed ID: 14986078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financial Impact of an Automated Oncology Dose-Rounding Initiative: One-Year Analysis.
    Dela-Pena JC; Eschenburg KA; LaRocca VW; Patel D; Hough SM
    JCO Clin Cancer Inform; 2021 Aug; 5():805-810. PubMed ID: 34351786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia.
    Brown LJ; La HA; Li J; Brunner M; Snoke M; Kerr AM
    Haemophilia; 2020 Aug; 26 Suppl 5():21-29. PubMed ID: 32935399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating cost savings in cytotoxic leftover management: A prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology.
    El Baraka S; Cherif Chefchaouni A; Bourdaime A; Ouedraogo JM; Shytry O; Belahcen MJ; Rahali Y
    J Oncol Pharm Pract; 2023 Sep; ():10781552231203403. PubMed ID: 37728162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost savings analysis and toxicity audit of a bevacizumab dose rounding policy at a community cancer center.
    Moore DC; McVey GN
    J Oncol Pharm Pract; 2018 Jan; 24(1):42-46. PubMed ID: 27760811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings.
    Jarkowski A; Nestico JS; Vona KL; Khushalani NI
    J Oncol Pharm Pract; 2014 Feb; 20(1):47-50. PubMed ID: 23512270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.